Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated for Age-Related Macular Degeneration.
10.3341/jkos.2013.54.10.1534
- Author:
Jung Jin LEE
1
;
Young Ju LEW
;
Sung Won CHO
;
Jong Woo KIM
Author Information
1. Myung-Gok Eye Research Institute, Department of Ophthalmology, Kim's Eye Hospital, Konyang University, Seoul, Korea. yjlew@kimeye.com
- Publication Type:Original Article
- Keywords:
Bevacizumab;
Exudative age-related macular degeneration;
Incidence;
Ranibizumab
- MeSH:
Antibodies, Monoclonal, Humanized;
Choroid*;
Choroidal Neovascularization*;
Eye*;
Humans;
Incidence*;
Macular Degeneration*;
Bevacizumab;
Ranibizumab
- From:Journal of the Korean Ophthalmological Society
2013;54(10):1534-1539
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the development of new choroidal neovascularization in fellow eyes of patients treated for unilateral exudative age-related macular degeneration (AMD). METHODS: Three hundred fourteen patients who were first diagnosed with unilateral exudative AMD and treated with intravitreal bevacizumab or ranibizumab were studied retrospectively. RESULTS: New exudative AMD developed in 7.0% of fellow eyes after 1 year, 10.8% after 2 years and 13.7% after more than 2 years. According to the subtype of exudative AMD, there were no significant differences between classic CNV, occult or minimally classic CNV, and PCV in the incidence of new exudative AMD. After 2 years, a higher conversion rate was found in the bevacizumab-treated group than the ranibizumab-treated group. CONCLUSIONS: The cumulative incidence of involvement in fellow eyes with exudative AMD was 13.7% over 2 years.
